Cisplatin News and Research

RSS

Psilocybin protects sensory nerves from chemotherapy damage in preclinical study

In mouse models, prophylactic psilocybin prevented or reduced multiple features of chemotherapy-induced peripheral neuropathy, with cycle-matched dosing sustaining protection during repeated cisplatin exposure without measurably affecting tumor growth. Experiments in human-derived sensory neurons and ex vivo peripheral nerves linked the effect to 5-HT2A-dependent preservation of mitochondrial trafficking and local axonal energy supply, while a nonhallucinogenic 5-HT2A agonist reproduced protection against mechanical hypersensitivity.

6 Sep 2026

Lab-grown mini tumors help scientists predict breast cancer treatment success

Researchers at UC San Francisco have developed a new method to predict how different types of breast cancer will respond to treatment, using patient data from the I-SPY2 breast cancer trial and rapid testing on lab-grown mini tumors.

11 Aug 2026

Autophagy modulation emerges as a strategy against cisplatin-resistant gastric cancer

Drug resistance remains one of the greatest obstacles to successful treatment of gastric cancer, limiting the long-term effectiveness of the widely used chemotherapy drug cisplatin.

6 Aug 2026

Ferroptosis-based therapy shows promise for advanced prostate cancer treatment

A recent review explores the rapidly expanding field of ferroptosis-based therapy for prostate cancer, presenting ferroptosis as a promising strategy to overcome resistance in advanced and castration-resistant prostate cancer (CRPC).

6 Aug 2026

Study identifies a novel direct drug target for head and neck squamous cell carcinoma

Chemotherapy remains a cornerstone of treatment for head and neck cancers, the seventh-most common cancer type worldwide.

6 Aug 2026

Excess EXO1 protein may drive cancer DNA damage and treatment response

When it comes to cancer, tumor suppressor genes are usually thought of as the "good guys." These genes make proteins that protect and repair DNA in cells.

21 May 2026

New mechanism to enhance precision in cancer drug development

Researchers at The University of Texas Medical Branch (UTMB) have identified how a key enzyme called ATR protects DNA from breaking when cells copy damaged genetic material, a discovery that could affect how certain cancer drugs are developed.

15 May 2026

Damon Runyon supports young scientists driving cancer research innovation

The Damon Runyon Cancer Research Foundation has named 13 new Damon Runyon Fellows, exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators.

11 Apr 2026

Clusterin inhibition offers new hope for treating cervical gastric-type adenocarcinoma

Gastric-type adenocarcinoma (GAS) is one of the most aggressive non-human papillomavirus (HPV)-associated cervical adenocarcinomas and remains especially difficult to diagnose and treat.

8 Apr 2026

Study reveals CAR T approach for hard-to-treat solid tumors

Chimeric antigen receptor T-cell therapy - CAR T for short - has been a major advance in treating blood cancers like leukemia and lymphoma.

30 Mar 2026

DNA nanomachine strategy reverses chemoresistance in small cell lung cancer

Professor Chao Zhang's team at Zhujiang Hospital, Southern Medical University, has developed a novel DNA nanomachine-based drug delivery and release strategy aimed at overcoming chemoresistance in small cell lung cancer (SCLC).

6 Mar 2026

Blocking growth hormone receptor may improve treatment response in lung cancer

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

2 Mar 2026

Study reveals long-term health risks after chemotherapy for testicular cancer

A large, multi-center study recently published online in the Journal of the National Comprehensive Cancer Network (JNCCN) provides new insight into the long-term health effects of contemporary chemotherapy regimens used to treat testicular cancer, highlighting differences in renal function, cardiovascular risk, and the overall burden of chronic health conditions among survivors.

19 Feb 2026

Blocking p300 restores chemotherapy sensitivity in resistant tumors

Overcoming tumor resistance to chemotherapy drugs has long been a challenge for oncology clinicians and researchers.

6 Feb 2026

Genetic insights into vestibular system damage from ototoxic drugs

The vestibular system is responsible for the sense of balance in the inner ear. Prolonged use of toxic substances, such as certain antibiotics or anticancer drugs, can damage the hair cells that form part of this system, leading to alterations in balance and other motor skills.

31 Oct 2025

Discovery of EUDAL reveals new mechanism behind chemotherapy resistance in oral cancer

Oral cancer is one of the most common head and neck cancers worldwide, with hundreds of thousands of new cases diagnosed every year. Despite advances in surgery, radiotherapy, and chemotherapy, survival rates remain poor.

30 Sep 2025

Proton therapy and IMRT show similar outcomes in head and neck cancer trial

A new phase III clinical trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer.

29 Sep 2025

Scientists uncover brain circuit that turns cravings into eating behavior

Researchers found that the bed nucleus of the stria terminalis integrates pleasure signals from central amygdala prodynorphin neurons and hunger signals from agouti-related peptide neurons to drive consumption. Manipulating this bed nucleus of the stria terminalis circuit bidirectionally altered food intake and body weight in mice.

11 Sep 2025

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC).

8 Sep 2025

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

8 Sep 2025

Cisplatin News and Research

Psilocybin protects sensory nerves from chemotherapy damage in preclinical study

Lab-grown mini tumors help scientists predict breast cancer treatment success

Autophagy modulation emerges as a strategy against cisplatin-resistant gastric cancer

Ferroptosis-based therapy shows promise for advanced prostate cancer treatment

Study identifies a novel direct drug target for head and neck squamous cell carcinoma

Excess EXO1 protein may drive cancer DNA damage and treatment response

New mechanism to enhance precision in cancer drug development

Damon Runyon supports young scientists driving cancer research innovation

Clusterin inhibition offers new hope for treating cervical gastric-type adenocarcinoma

Study reveals CAR T approach for hard-to-treat solid tumors

DNA nanomachine strategy reverses chemoresistance in small cell lung cancer

Blocking growth hormone receptor may improve treatment response in lung cancer

Study reveals long-term health risks after chemotherapy for testicular cancer

Blocking p300 restores chemotherapy sensitivity in resistant tumors

Genetic insights into vestibular system damage from ototoxic drugs

Discovery of EUDAL reveals new mechanism behind chemotherapy resistance in oral cancer

Proton therapy and IMRT show similar outcomes in head and neck cancer trial

Scientists uncover brain circuit that turns cravings into eating behavior

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News